Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Hyperion DeFi Inc (Hyperion), formerly Eyenovia Inc, is a is an ophthalmic technology company that carries out creating advanced technologies for administering eye medications. The company commercializes Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis and clobetasol propionate ophthalmic suspension for treating post-operative inflammation and pain following ocular surgery. The company also develops the Optejet delivery system for use with the drug-device therapeutic program. Hyperion is headquartered in Laguna Hills, California, the US.
Headquarters
United States of America
Address
Suite 390, South Point Drive, Laguna Hills, California, 23461
Website
www.hyperiondefi.com
No of Employees
9
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HYPD (NASD)
Revenue (2024)
$813,500
1318.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
9%
(2024 vs 2023)
Market Cap*
$35.5M
Net Profit Margin (2024)
XYZ
93.6%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Optejet | Optejet |
| MydCombi (Tropicamide and Phenylephrine HCL Ophthalmic Spray): Mydriasis | Mydcombi |
| Clobetasol Propionate Ophthalmic Suspension: Post-Operative Inflammation and Pain Following Ocular Surgery |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Corporate Changes/Expansions | In July, the company changed its name to Hyperion DeFi Inc. |
| 2025 | Contracts/Agreements | In March, the company entered into a non-binding letter of intent to merge with Betaliq, Inc. |
| 2024 | Contracts/Agreements | In August, the company announced that it has signed a non-binding agreement with Taiwan-based Formosa Pharmaceuticals to co-develop a formulation of clobetasol propionate ophthalmic suspension. |
Competitor Comparison
| Key Parameters | Hyperion DeFi Inc | EyePoint Inc | Outlook Therapeutics Inc | Allergan USA Inc | Titan Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Laguna Hills | Watertown | Iselin | Irvine | New York |
| State/Province | California | Massachusetts | New Jersey | California | New York |
| No. of Employees | 9 | 214 | 17 | - | 4 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Hyunsu Jung | Chief Investment Officer; Chief Executive Officer; Director | Executive Board | 2026 | 30 |
| David Knox | Chief Financial Officer | Senior Management | 2025 | 36 |
| Robert Rubenstein | General Counsel | Senior Management | 2026 | 59 |
| Happy Walters | Director | Non Executive Board | 2025 | 59 |
| Ellen Strahlman, M.D. | Director | Non Executive Board | 2022 | 68 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer